Want to see GB:FUM full AI Analyst Report?
Futura Medical (FUM) AI Stock Analysis
Futura Medical
(LSE:FUM)
The score is primarily constrained by volatile financial performance, substantial 2025 losses and cash burn, and weak technical momentum. Zero debt provides meaningful financial stability, but negative earnings and the lack of dividend support keep the overall score low.
Futura Medical (FUM) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 593.83K
- Dividend Yield
- ―
- Average Volume (3M)
- 10.18M
- Price to Earnings (P/E)
- -0.3
- Beta (1Y)
- 0.83
- Revenue Growth
- -70.77%
- EPS Growth
- 60.39%
- Country
- UK
- Employees
- 14
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Futura Medical Business Overview & Revenue Model
Company Description
Futura Medical plc operates as a pharmaceutical firm specializing in the creation and advancement of consumer healthcare products. The company primarily targets the sexual health and pain management sectors. Its leading innovation is MED3000, a topic...
How the Company Makes Money
Futura Medical’s business model is primarily based on out-licensing and commercial partnerships rather than building a large in-house salesforce. The company makes money by granting partners the rights to manufacture, market and sell its ED gel (MED3...
Futura Medical Earnings Call Summary
The earnings call reflected significant financial and operational challenges with revenue shortfalls, unexpected market performance, and inventory issues. While there are promising R&D developments, these are long-term. Immediate financial pressures and market challenges dominate the current outlook.
Q2-2025 Updates
Positive Updates
Negative Updates
Company Guidance
During the investor presentation call for Futura Medical plc, Interim CEO Alex Duggan provided guidance indicating that the company's full-year 2025 performance is expected to fall significantly below market expectations due to challenges in sustaining consumer uptake and lower-than-anticipated repeat sales. Despite launching in seven countries in H1, the initial strong trials did not translate into continued sales, affecting supply volumes and royalty streams. Angela Hildreth reported a revenue of just over GBP 1 million for the first half of 2025, with a gross profit of GBP 0.7 million, but also highlighted a GBP 0.49 million provision for inventory obsolescence. The company incurred an exceptional charge of GBP 3.6 million due to impairment of U.S. plant and equipment, contributing to a loss after tax of GBP 6.6 million. The adjusted loss after tax was GBP 1.9 million, with cash reserves at GBP 3.69 million at the period's end. Full-year sales for 2025 are now projected to be between GBP 1.3 million and GBP 1.4 million, with cash reserves reduced to GBP 2.7 million by the end of August. The company is actively exploring commercial and financing options to extend its cash runway, which currently runs into January 2026.
Futura Medical Financial Statement Overview
Summary
Strong balance-sheet stability from zero debt is offset by the sharp 2025 revenue decline, heavy losses, negative equity return, and operating cash burn.
Income Statement
35NegativeBalance Sheet
85Very PositiveCash Flow
45Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.32M | 1.70M | 13.93M | 3.10M | 0 | 0 |
| Gross Profit | 2.44M | 1.24M | 9.57M | 1.77M | -24.73K | -19.81K |
| EBITDA | -152.48K | -5.54M | 1.41M | -6.83M | -6.85M | -5.85M |
| Net Income | -3.67M | -9.07M | 1.29M | -6.51M | -5.85M | -4.96M |
Balance Sheet | ||||||
| Total Assets | 4.15M | 5.22M | 13.59M | 11.82M | 6.47M | 11.80M |
| Cash, Cash Equivalents and Short-Term Investments | 1.24M | 3.40M | 6.60M | 7.71M | 4.03M | 10.37M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 2.15M | 2.41M | 4.63M | 6.34M | 1.75M | 2.08M |
| Stockholders Equity | 2.01M | 2.81M | 8.96M | 5.48M | 4.72M | 9.72M |
Cash Flow | ||||||
| Free Cash Flow | -4.79M | -5.58M | -1.29M | -935.60K | -6.52M | -4.29M |
| Operating Cash Flow | -4.79M | -5.58M | 438.41K | 570.25K | -5.78M | -3.87M |
| Investing Cash Flow | 0 | 38.19K | -1.73M | -1.43M | -740.70K | -419.72K |
| Financing Cash Flow | 2.35M | 2.38M | 170.91K | 4.55M | 169.58K | 13.65M |
Futura Medical Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:FUM, the sentiment is Negative. The current price of 0.18 is below the 20-day moving average (MA) of 0.20, below the 50-day MA of 0.24, and below the 200-day MA of 0.71, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 41.78 is Neutral, neither overbought nor oversold. The STOCH value of 54.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:FUM.
Futura Medical Peers Comparison
Overall Rating
GB:SBTX59Neutral
GB:AREC49.4Neutral
GB:POLB46Neutral- GB:FUM45Neutral
GB:AVCT43Neutral
GB:OPTI41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| GB:SBTX | 59Neutral | GBP 13.61M | -29.17 | -5.25% | ― | 95.16% | 85.60% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| GB:AREC | 49Neutral | GBP 37.37M | 165.00 | 3.75% | ― | ― | ― |
| GB:POLB | 46Neutral | GBP 49.62M | -8.33 | -71.28% | ― | ― | 31.58% |
| GB:FUM | 45Neutral | GBP 2.59M | -0.28 | -152.41% | ― | -70.77% | 60.39% |
| GB:AVCT | 43Neutral | GBP 294.51M | -6.63 | -1293.07% | ― | ― | ― |
| GB:OPTI | 41Neutral | GBP 5.99M | -1.40 | -77.85% | ― | 11.90% | -2864.29% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:FUM | Futura Medical | 0.17 | -2.43 | -93.27% | |
| GB:AVCT | Avacta Group plc | 60.50 | -11.50 | -15.97% | |
| GB:OPTI | OptiBiotix Health | 5.80 | -2.20 | -27.50% | |
| GB:SBTX | SkinBioTherapeutics plc | 5.25 | -10.88 | -67.44% | |
| GB:POLB | Poolbeg Pharma Ltd. | 6.50 | 2.65 | 68.83% | |
| GB:AREC | Arecor Therapeutics PLC | 82.50 | 11.00 | 15.38% |
Futura Medical Corporate Events
Futura Medical reshapes finance leadership as sale talks advance
NeutralFutura Medical has announced that Finance Director and Chief Operating Officer Angela Hildreth will step down from her executive roles in mid-November, but will remain on the board as a non-executive director during the company’s ongoing strate...
Futura Medical’s Eroxon Intense Delivers Strong Home Test Results Ahead of 2027 Launch
PositiveFutura Medical has reported highly positive results from an additional Home User Test of its new Eroxon Intense formulation, planned for commercial launch in the first half of 2027. The updated, optimised presentation is designed to improve sensorial...
Futura Medical Directors Boost Stakes After Fundraise
PositiveFutura Medical has disclosed that its directors subscribed for 23,500,000 new ordinary shares following the completion of a recent fundraise. The purchases, all executed on the London Stock Exchange at 0.2p per share, underline senior management̵...
Futura Medical Shareholders Back Major Fundraise to Support Sexual Health Growth Strategy
PositiveFutura Medical plc, the AIM-listed consumer healthcare group behind Eroxon, specialises in innovative sexual health products for men and women. Its portfolio spans over-the-counter treatments for erectile dysfunction and development-stage gels target...
Futura Medical Wins Shareholder Backing for Major Fundraise and Share Capital Expansion
PositiveFutura Medical shareholders have overwhelmingly approved all resolutions at a general meeting, clearing the way for the company’s previously announced placing, subscription and retail offer to proceed. The vote confirms strong investor backing...
Futura Medical Streamlines Board as Non-Executive Director Roy Davis Steps Down
NeutralFutura Medical has announced that Non-Executive Director Roy Davis will step down from the board on 20 October 2026, following a review of his wider board commitments and time requirements. The company stressed that his departure is not related to bu...
Futura Medical Upsizes Oversubscribed Retail Offer, Targets £1.8m Funding
PositiveFutura Medical has conditionally raised £200,000 from an oversubscribed retail offer on the BookBuild platform, increasing the planned amount from £150,000 through the issue of 100,000,000 new ordinary shares. Together with prior firm and c...
Futura Medical Calls General Meeting as Part of Fundraise Process
PositiveFutura Medical has sent shareholders a circular and notice convening a general meeting as part of its recently announced fundraise, underscoring ongoing efforts to support the commercial rollout of its sexual health portfolio. The meeting will be hel...
Futura Medical launches deep-discount retail offer to shore up cash and support sale process
NegativeFutura Medical has launched a retail offer via the BookBuild platform to existing UK shareholders, seeking to raise up to £150,000 through the issue of up to 75 million new shares at 0.2 pence, a 37.6% discount to the prior closing price. This f...
Futura Medical Launches Fundraise and Formal Sale Process as Sexual Health Portfolio Grows
NegativeFutura Medical has launched a multi-part equity fundraising of approximately £1.6 million through firm and conditional placings and a subscription, with an additional retail offer of up to £150,000 at 0.2 pence per share, alongside issuing...
Futura Medical trims losses, reshapes U.S. strategy as cash runway narrows
NegativeFutura Medical reported interim results showing revenue of £1.62 million for the first half of 2026, largely driven by a settlement with former U.S. partner Haleon, while underlying royalties from Eroxon remained modest and cash fell to £1....
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 27, 2026